Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation

Philip J. Bierman, John W. Sweetenham, Fausto R. Loberiza, Goli Taghipour, Hillard M. Lazarus, J. Douglas Rizzo, Norbert Schmitz, Koen Van Besien, Julie M. Vose, Mary Horowitz, Anthony Goldstone

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Purpose: To compare results of syngeneic, allogeneic, and autologous hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma (NHL). Patients and Methods: The databases of the International Bone Marrow Transplant Registry (IBMTR) and the European Group for Blood and Marrow Transplantation were used to identify 89 NHL patients who received syngeneic transplants. These patients were compared with NHL patients identified from the IBMTR and the Autologous Blood and Marrow Transplant Registry who received allogeneic (T-cell depleted and T-cell replete) and autologous (purged and unpurged) transplants. Results: No significant differences in relapse rates were observed when results of allogeneic transplantation were compared with syngeneic transplantation for any histology. T-cell depletion of allografts was not associated with a higher relapse risk, but was associated with improved overall survival for patients with low-grade and intermediate-grade histology. Patients who received unpurged autografts for low-grade NHL had a five-fold (P = .008) greater risk of relapse than recipients of syngeneic transplants, and recipients of unpurged autografts had a two-fold (P = .0009) greater relapse risk than patients who received purged autografts. Among low-grade NHL patients, the use of purging was associated with significantly better disease-free survival (P = .003) and overall survival (P = .04) when compared with patients who received unpurged autografts. Conclusion: These analyses failed to find evidence of a graft-versus-lymphoma effect, but do provide indirect evidence to support the hypothesis that tumor contamination may contribute to lymphoma relapse, and that purging may be beneficial for patients undergoing autologous hematopoietic stem-cell transplantation for low-grade NHL.

Original languageEnglish (US)
Pages (from-to)3744-3753
Number of pages10
JournalJournal of Clinical Oncology
Volume21
Issue number20
DOIs
StatePublished - Oct 15 2003

Fingerprint

Autologous Transplantation
Hematopoietic Stem Cell Transplantation
Homologous Transplantation
Non-Hodgkin's Lymphoma
Registries
Lymphoma
Bone Marrow
Transplants
Autografts
Recurrence
T-Lymphocytes
Histology
Isogeneic Transplantation
Survival
Disease-Free Survival
Allografts
Databases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma : A comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. / Bierman, Philip J.; Sweetenham, John W.; Loberiza, Fausto R.; Taghipour, Goli; Lazarus, Hillard M.; Rizzo, J. Douglas; Schmitz, Norbert; Van Besien, Koen; Vose, Julie M.; Horowitz, Mary; Goldstone, Anthony.

In: Journal of Clinical Oncology, Vol. 21, No. 20, 15.10.2003, p. 3744-3753.

Research output: Contribution to journalArticle

@article{af8564c8652c4224ae7e267aa2765695,
title = "Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation",
abstract = "Purpose: To compare results of syngeneic, allogeneic, and autologous hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma (NHL). Patients and Methods: The databases of the International Bone Marrow Transplant Registry (IBMTR) and the European Group for Blood and Marrow Transplantation were used to identify 89 NHL patients who received syngeneic transplants. These patients were compared with NHL patients identified from the IBMTR and the Autologous Blood and Marrow Transplant Registry who received allogeneic (T-cell depleted and T-cell replete) and autologous (purged and unpurged) transplants. Results: No significant differences in relapse rates were observed when results of allogeneic transplantation were compared with syngeneic transplantation for any histology. T-cell depletion of allografts was not associated with a higher relapse risk, but was associated with improved overall survival for patients with low-grade and intermediate-grade histology. Patients who received unpurged autografts for low-grade NHL had a five-fold (P = .008) greater risk of relapse than recipients of syngeneic transplants, and recipients of unpurged autografts had a two-fold (P = .0009) greater relapse risk than patients who received purged autografts. Among low-grade NHL patients, the use of purging was associated with significantly better disease-free survival (P = .003) and overall survival (P = .04) when compared with patients who received unpurged autografts. Conclusion: These analyses failed to find evidence of a graft-versus-lymphoma effect, but do provide indirect evidence to support the hypothesis that tumor contamination may contribute to lymphoma relapse, and that purging may be beneficial for patients undergoing autologous hematopoietic stem-cell transplantation for low-grade NHL.",
author = "Bierman, {Philip J.} and Sweetenham, {John W.} and Loberiza, {Fausto R.} and Goli Taghipour and Lazarus, {Hillard M.} and Rizzo, {J. Douglas} and Norbert Schmitz and {Van Besien}, Koen and Vose, {Julie M.} and Mary Horowitz and Anthony Goldstone",
year = "2003",
month = "10",
day = "15",
doi = "10.1200/JCO.2003.08.054",
language = "English (US)",
volume = "21",
pages = "3744--3753",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "20",

}

TY - JOUR

T1 - Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma

T2 - A comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation

AU - Bierman, Philip J.

AU - Sweetenham, John W.

AU - Loberiza, Fausto R.

AU - Taghipour, Goli

AU - Lazarus, Hillard M.

AU - Rizzo, J. Douglas

AU - Schmitz, Norbert

AU - Van Besien, Koen

AU - Vose, Julie M.

AU - Horowitz, Mary

AU - Goldstone, Anthony

PY - 2003/10/15

Y1 - 2003/10/15

N2 - Purpose: To compare results of syngeneic, allogeneic, and autologous hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma (NHL). Patients and Methods: The databases of the International Bone Marrow Transplant Registry (IBMTR) and the European Group for Blood and Marrow Transplantation were used to identify 89 NHL patients who received syngeneic transplants. These patients were compared with NHL patients identified from the IBMTR and the Autologous Blood and Marrow Transplant Registry who received allogeneic (T-cell depleted and T-cell replete) and autologous (purged and unpurged) transplants. Results: No significant differences in relapse rates were observed when results of allogeneic transplantation were compared with syngeneic transplantation for any histology. T-cell depletion of allografts was not associated with a higher relapse risk, but was associated with improved overall survival for patients with low-grade and intermediate-grade histology. Patients who received unpurged autografts for low-grade NHL had a five-fold (P = .008) greater risk of relapse than recipients of syngeneic transplants, and recipients of unpurged autografts had a two-fold (P = .0009) greater relapse risk than patients who received purged autografts. Among low-grade NHL patients, the use of purging was associated with significantly better disease-free survival (P = .003) and overall survival (P = .04) when compared with patients who received unpurged autografts. Conclusion: These analyses failed to find evidence of a graft-versus-lymphoma effect, but do provide indirect evidence to support the hypothesis that tumor contamination may contribute to lymphoma relapse, and that purging may be beneficial for patients undergoing autologous hematopoietic stem-cell transplantation for low-grade NHL.

AB - Purpose: To compare results of syngeneic, allogeneic, and autologous hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma (NHL). Patients and Methods: The databases of the International Bone Marrow Transplant Registry (IBMTR) and the European Group for Blood and Marrow Transplantation were used to identify 89 NHL patients who received syngeneic transplants. These patients were compared with NHL patients identified from the IBMTR and the Autologous Blood and Marrow Transplant Registry who received allogeneic (T-cell depleted and T-cell replete) and autologous (purged and unpurged) transplants. Results: No significant differences in relapse rates were observed when results of allogeneic transplantation were compared with syngeneic transplantation for any histology. T-cell depletion of allografts was not associated with a higher relapse risk, but was associated with improved overall survival for patients with low-grade and intermediate-grade histology. Patients who received unpurged autografts for low-grade NHL had a five-fold (P = .008) greater risk of relapse than recipients of syngeneic transplants, and recipients of unpurged autografts had a two-fold (P = .0009) greater relapse risk than patients who received purged autografts. Among low-grade NHL patients, the use of purging was associated with significantly better disease-free survival (P = .003) and overall survival (P = .04) when compared with patients who received unpurged autografts. Conclusion: These analyses failed to find evidence of a graft-versus-lymphoma effect, but do provide indirect evidence to support the hypothesis that tumor contamination may contribute to lymphoma relapse, and that purging may be beneficial for patients undergoing autologous hematopoietic stem-cell transplantation for low-grade NHL.

UR - http://www.scopus.com/inward/record.url?scp=0142023893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142023893&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.08.054

DO - 10.1200/JCO.2003.08.054

M3 - Article

C2 - 12963703

AN - SCOPUS:0142023893

VL - 21

SP - 3744

EP - 3753

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 20

ER -